Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Decrease of p38 MAPK phosphorylation in HL60 and KG1a cells exposed to 5-Fluorouridine (FUrd) after cell pretreatment with p38 MAPK pathway inhibitor SB202190. by Sabine Matou-Nasri (2938941)

Pairwise correlations in APP/PS1 mice are decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Pathway analysis of pediatric autoimmune hepatitis (AIH) samples (n = 5) compared to pediatric normal (pNormal) controls (n = 9). by Alyssa Kriegermeier (4707226)

Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …”

IgA is decreased in individual donor milk and is present in human milk-based fortifiers. by Christian Tamar (21100605)

Fig 5 - by Arjen Tilstra (6915227)

Primary small molecule screen to identify attenuators of CSE-induced decrease in size and increase in MUC5AC. by Pranjali Beri (14945400)

“…Hit compounds at 1 and 10μM concentrations that <b>B)</b> increased spheroid size (swell) or <b>C)</b> decreased MUC5AC staining in the lumen relative to DMSO and CSE 3%-treated bronchospheres. …”

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

Image_5_Topoisomerase 2B Decrease Results in Diastolic Dysfunction via p53 and Akt: A Novel Pathway.TIF by Rohit Moudgil (540119)

Image_5_Topoisomerase 2B Decrease Results in Diastolic Dysfunction via p53 and Akt: A Novel Pathway.TIF by Rohit Moudgil (540119)

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

“…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

“…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”

Cardamonin decreased the content of free fatty acids and the activity of CPT-1. by Peiguang Niu (17044532)

Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

Cardamonin decreased the protein level of Raptor and suppressed lipogenesis and CPT-1. by Peiguang Niu (17044532)

Supplementary Material for: Cardiac Troponin Is Elevated in Patients with Thyrotoxicosis and Decreases as Thyroid Function Improves and Brain Natriuretic Peptide Levels Decrease by Watanabe N. (4118812)

“…At baseline, median hsTnI was 1.9 pg/mL and ranged from 0 to 69.6 pg/mL. Five patients (3.5%) had a high hsTnI value that exceeded 26.2 pg/mL, which is used as the cutoff for diagnosis of myocardial infarction, and 22 patients (15.4%) had an intermediate value between 5.0 and 26.2 pg/mL. …”